Pseudomonas aeruginosa and Klebsiella pneumoniae Adaptation to Innate Immune Clearance Mechanisms in the Lung

Sebastian A. Riquelme  Danielle Ahn  Alice Prince
Department of Pediatrics, Columbia University Medical Center, New York, NY, USA

Keywords
Pseudomonas aeruginosa  ·  Klebsiella pneumoniae  ·  Biofilm  ·  Bacterial adaptation  ·  Immune evasion  ·  Cystic fibrosis  ·  Bacterial infection  ·  Inflammasome  ·  Pathogen-associated molecular patterns  ·  Reactive oxygen species

Abstract
Many different species of gram-negative bacteria are associated with infection in the lung, causing exacerbations of chronic obstructive pulmonary disease, cystic fibrosis (CF), and ventilator-associated pneumonias. These airway pathogens must adapt to common host clearance mechanisms that include killing by antimicrobial peptides, antibiotics, oxidative stress, and phagocytosis by leukocytes. Bacterial adaptation to the host is often evident phenotypically, with increased extracellular polysaccharide production characteristic of some biofilm-associated organisms. Given the relatively limited repertoire of bacterial strategies to elude airway defenses, it seems likely that organisms sharing the same ecological niche might also share common strategies to persistently infect the lung. In this review, we will highlight some of the major factors responsible for the adaptation of Pseudomonas aeruginosa to the lung, addressing how growth in biofilms enables persistent infection, relevant to, but not limited to, the pathogenesis of infection in CF. In contrast, we will discuss how carbapenem-resistant Klebsiella pneumoniae evade immune clearance, an organism often associated with ventilator-associated pneumonia and health-care-acquired pneumonias, but not a typical pathogen in CF.

Introduction
The gram-negative airway pathogens, Pseudomonas aeruginosa and Klebsiella pneumoniae, are opportunists that are inadvertently inhaled and, upon finding a conducive environment, rapidly adjust gene expression to proliferate. This entails major changes: the upregulation of genes involved in the acquisition of newly available carbon sources, the scavenging of essential nutrients, such as iron, and the positive selection for clones resistant to immune clearance mechanisms. Mutations in genes that potentially impact both major processes would likely be under significant positive selection. A substantial literature...
has been amassed detailing how many organisms form biofilms in pulmonary and endovascular infections as well as a mode of infection on abiotic surfaces. Many features of biofilms contribute to bacterial persistence and the survival of the bacterial community within the lung. These processes are highly relevant to numerous forms of infection, including colonization of endotracheal tubes, airways, and intravascular and urinary catheters. In addition, recent findings suggest host immunity to play a key role during bacterial adaptation, which, in conjunction with the ability of these pathogens to adapt a biofilm lifestyle, are a matter of discussion in this review.

**Gram-Negative Bacteria and Lung Inflammation: Cystic Fibrosis**

Interactions of bacterial pathogens and innate immune signaling have been well studied but not fully understood in cystic fibrosis (CF) [1]. CF is a genetic disease initially linked to the Caucasian population and now recognized in recent studies in much of the rest of the world population [2–5]. CF is produced by mutations in the CF transmembrane conductance regulator (CFTR), a chloride channel at the surface of epithelial and immune cells [1]. As hydration and mucin viscosity in the airways is dependent on the ionic equilibrium across the epithelial barrier, lack of CFTR function reduces airway mucus fluidity, trapping inhaled bacteria [6]. Although CFTR mutations also have negative effects on the function of other organs, such as the pancreas, CF patients receiving nutritional supplementation are able to manage these limitations [7]. However, the inflammation and chronic infection associated with CF lung disease limits quality of life and ultimately longevity [8].

During childhood, most CF patients are colonized by both *P. aeruginosa* and *Staphylococcus aureus*. However, later in adulthood, the primary pathogen causing pulmonary infection in CF is *Pseudomonas* [1]. Many studies have addressed why *P. aeruginosa* is the major pathogen in CF. The most commonly accepted hypothesis suggests that physiological abnormalities linked to CFTR mutations confer advantages to *P. aeruginosa* over others pathogens. These advantages include mucus viscosity, excessive production of reactive oxygen species (ROS), impaired autophagy, reduced airway acidity, and accumulation of ceramides, all factors that contribute to the genomic and metabolic plasticity of *P. aeruginosa* and its ability to colonize the airways [9]. Whether the exaggerated inflammatory response seen in CF facilitates the colonization and then chronicity of *P. aeruginosa* infection over other bacteria is not well understood, although recent findings suggest that mutant CFTR directly influences inflammatory signaling, and this favors *P. aeruginosa* over other respiratory pathogens, such as *S. aureus* and *K. pneumoniae* [10].

In this work, we review the recent literature detailing how *P. aeruginosa* adapts to the CF lung through interactions with host immunity and the metabolic environment of the airways. We also highlight how the mechanisms of patho-adaptation that are operative for *P. aeruginosa* are conserved among lung pathogens by reviewing the pathways by which *K. pneumoniae*, another clinically relevant multidrug-resistant (MDR) gram-negative pathogen, causes airway invasion.

**P. aeruginosa Adaptation to the Airways through Biofilm Formation**

Biofilm formation is a highly conserved mechanism of bacterial adaptation, which has been well studied in the setting of CF, and endovascular and foreign body infections, and common mechanisms pertain to many clinical settings. *P. aeruginosa* responds to a surface through the activation of WspR and the cyclic (c)-di-GMP cascade [11–13] (Fig. 1). The c-di-GMP cascade controls expression of over 500 genes [11, 14]. Initial probiofilm stimuli can be chemotactic or metabolic. These include operons that regulate twitching motility through the upregulated expression of type IV pili, as well as by decreasing swimming motility through suppression of flagellin gene expression. WspR signaling is critical in the expression of *pslA* and *pelA*, genes that encode the structural components that lead to biofilm formation [15] (Fig. 1a, b). In the process of pulmonary colonization and chronic infection, there is selection for both small colony variants and mucoid variants. Organisms generally produce either a Pel or Psl predominant biofilm [16]. The Pel-directed biofilm, which refers to the formation of *Pseudomonas* pellicles on the surface of cultures, is a polymer of N-acetyl-galactosamine and N-acetyl-glucosamine [15, 17]. The Psl operon results in the formation of a biofilm matrix composed of mannose, rhamnose, and glucose [15, 18]. *P. aeruginosa* can also become mucoid, a property conferred by the activation of the *alg* operon, which in the presence of the *mucA* mutation activates gene expression to cause production of copious extracellular polysaccharides composed of repeating subunits of guluronic and mannuric acids [19, 20]. Mucoid phenotypes are related with infectious chronicity [21].

Bacterial Adaptation to the Airways

J Innate Immun 2018;10:442–454
DOI: 10.1159/000487515

443
Fig. 1. *Pseudomonas aeruginosa* biofilm production and interactions with host immunity. **A** Airway epithelial cells contact *P. aeruginosa* during infection triggering chemotactic signaling and biofilm production. Polysaccharide structures generated by bacterial metabolism are anchored to the extracellular matrix of these cells. **B** *P. aeruginosa* metabolic pathways provide biofilm components. Intracellular pathways that direct the metabolism of glucose (green arrows) through the Entner-Doudoroff (central loci *zwf* and *glk*) and glyoxylate shunt (mediated by *aceA* and *gcb*) pathways. Glucose flux through these pathways allows the production of carbohydrates that form extracellular polysaccharides for the attachment to the airway cells. Upon contact with the host cell, surface recognition and activation of WspR and cyclic (c)-di-GMP production (red arrows) result in stimulation of *lasR* and *rhlR* loci and production of PslA and PelA, which support formation of extracellular polysaccharides, c-di-GMP coordinates biofilm formation and bacterial motility, switching from flagellar- to a pilus-dependent twitching motility through activation of the PIY1/chpAK complex. Both endogenous/exogenous reactive oxygen species (ROS) sources and catabolite repressor succinate collaborate in the synthesis of c-di-GMP. Intracellular ROS and redox balance are regulated by NADPH generated by *zwf* activity. **C** *P. aeruginosa* interaction with host immunity. Pathogen-associated molecular patterns, such as lipopolysaccharide (LPS), flagella, pilus, or type three secretion system components (TTSS), activate proinflammatory surface receptors in immune cells. Both TLR4/MD2-LPS and TLR5-flagella surface interactions trigger activation of transcription factor NF-κB and mitochondrial destabilization (purple arrows). NF-κB induces production and secretion of inflammatory cytokines, such as IL-6 and IL-8. Mitochondrial collapse is accompanied by accumulation of ROS and succinate release and hypoxia-induced factor-1α (HIF1α) stabilization, which acts as a transcription factor that mediates production of pro-IL-1β (black arrows). Pro-IL-1β is cleaved to its mature form by caspase-1 produced by three different inflammasome systems: (1) NAIP/NLRC4/ASC activated by cytoplasmic uptake of flagellin; (2) NLRP3/ASC activated by cytoplasmic uptake of LPS; and (3) pilin secreted by *P. aeruginosa.*
Bacterial Adaptation to the Airways

Biofilms and Oxidant Stress

Several stimuli for the production of such biofilms have been proposed, most importantly oxidant stress. It is apparent that endogenous oxidant stress is sufficient, as organisms exposed to H₂O₂ spin off mucoid variants in vitro [22], a process that is blocked in the presence of an antioxidant such as N-acetyl cysteine. The extracellular polysaccharides themselves can also contribute to protection from ROS [16]. In addition to the oxidant stress generated by bacterial metabolism, which for P. aeruginosa is preferentially oxidative, there are numerous sources of oxidant stress in vivo. In a clinical setting such as CF, organisms are continually exposed to antimicrobial agents, which, despite their specific bacterial targets, wind up killing through the production of toxic oxidants [23]. Low-level exposure to aminoglycosides, as well as the fluoroquinolones that induce DNA damage, presents a major inducer of oxidant stress within the bacteria and inhibits bacterial growth. The recruitment of immune cells and their release of oxidants, such a mitochondrial-related anion superoxide (O₂⁻) are highly toxic oxidants as well. The organisms isolated from clinical settings often have upregulated expression of DNA repair mechanisms and are observed to have increased mutation rates in response to oxidant stress encountered from the host response.

Bacterial metabolism must be very significantly altered to support the bioenergetic demands of biofilm formation. This adaptation has been termed “metabolic adaptation” [24, 25]. The metabolic changes provide a mechanism to diminish oxidant production and to enhance the production of NADPH, which promotes the formation of antioxidants, as opposed to NADH, which is prooxidant. This can be accomplished through increased Entner-Doudoroff activity, a catabolic route for glucose, which increases NADPH production and diverts the energetic program away from ATP generation through the more oxidant tricarboxylic acid (TCA) cycle activity [26]. In order to optimize extensive polysaccharide production, key components of the alginate and/or biofilm matrix, metabolic adaptation can also be associated with increased use of the glyoxylate shunt to generate even more carbohydrate substrates [27]. Thus, the generation of extracellular polysaccharide matrices may well be primarily a response to oxidant stress encountered in vivo.

c-di-GMP signaling also results in the suppression of motility, and, with it, decreased expression of gene products that can activate inflammasomes including flagellin [14]. In addition, there is suppression of the type three secretion system (TTSS) components which activate the inflammasome. TTSS toxins themselves alter the integrity of the epithelial tight junctions [28] and cause widespread damage in the lung through a patatin-like activity [29, 30]. The consequences of this global downregulation of immunostimulatory activity have been interpreted as a mechanism to avoid immune clearance.

Biofilms and Innate Immune Clearance Mechanisms

The major driving force for biofilm formation in vivo has been thought to be resistance to innate immune clearance. The biofilm community, overall, affords physical protection to a substantial amount of the biomass, as the organisms are protected from phagocytes, antibody, and complement [16]. The biomass also provides a diversity of microenvironments exposed to different levels of oxygenation and nutrients, diversity that overall may enhance the viability of the biofilm community. In vitro studies are less clear-cut. The extracellular polysaccharides associated with biofilms do not appear to constitute a significant barrier to antimicrobial penetration [31], as they form a loose polysaccharide mesh. Depending upon the nature of the biofilm matrix, whether formed of alginate, or Pel or PslA polymers, there may or may not be an effect of charge on antibiotic diffusion.

Whether biofilms arise as a response to phagocytic clearance is not definitively established. While the prevailing dogma suggests that mucoid or biofilm-producing P. aeruginosa are “resistant” to phagocytic clearance, supporting data are limited, although there are few, if any, murine model systems that faithfully reproduce what happens in humans. Moreover, confusion as to the predominance of the Pel or Psl biofilm components, as opposed to the production of alginate, has made interpretation of the importance of each of these genes in pathogenesis difficult [15, 17]. Models of infection performed with P. aeruginosa mutants lacking specific biofilm components and/or the ability to produce alginate reflect the relative contribution of these extracellular polysaccharides to the pathogenesis of pulmonary infection [32]. While an immunostimulatory activity and complement resistance could be ascribed to the expression of Pel, a mucoid strain expressing Pel was readily cleared from the murine lung in an acute infection model, suggesting that phagocytic clearance is not at all adversely affected by the presence of these extracellular polysaccharides [32]. While the presence of alginate or biofilm-specific antibodies to promote clearance of these strains has been pro-

Bacterial Adaptation to the Airways

J Innate Immun 2018;10:442–454
DOI: 10.1159/000487515

445
posed, experiments done in infection-naïve mice indicate that this is not the case, at least in the murine model.

The ability to proliferate in both planktonic as well as biofilm modes of growth is undoubtedly a major factor in the success of *P. aeruginosa* as an opportunistic pathogen. While it is unclear exactly how the bacterial population shifts to biofilm formation in vivo, it seems likely that some critical number of organisms must reach the epithelial surface to activate the bacterial chemosensors that would initiate c-di-GMP signaling and biofilm formation [14]. The planktonic organisms that are presumably the initial sources of infection are generally motile, express immunostimulatory lipopolysaccharide (LPS) and other pathogen-associated molecular patterns (PAMPs) and should activate the numerous protective responses in the airways. Thus, the infecting organisms must have specific mechanisms to evade this initial innate immune response.

**P. aeruginosa Resistance to Antimicrobial Peptides**

The airway epithelium, through the effects of IL-22 and other cytokines and interferons, produces a large number of antimicrobial peptides [33]. Many organisms, including *P. aeruginosa*, are able to undergo mutation to acquire resistance to antimicrobial peptides, which would enhance their ability to persistently infect epithelial surfaces. An important site of *P. aeruginosa* infection is the eye, where these organisms are an important cause of keratitis [34, 35]. A major therapeutic strategy against these biofilm infections is the development of optimized antimicrobial peptides delivered topically [36]. There is substantial interest in the development of more active antimicrobial peptides that could be used topically to treat organisms growing at various anatomical sites, whether in a planktonic or biofilm format.

**Resistance to Inflammasome-Mediated Clearance**

*P. aeruginosa* can be especially virulent pathogens, expressing potent toxins, both proteases and the more complex TTSS that target specific eukaryotic receptors [37]. They express multiple PAMPs associated with the activation of inflammasomes (Fig. 1c): intracellular flagellin can be detected by the NLRC4/NAIP-dependent inflammasome, which causes caspase-1 maturation and pro-IL-1β cleavage, producing its secretion [38–40]. Flagellin can also activate surface TLR5 receptors to induce NF-κB-dependent inflammation [41]. LPS, which is recognized by the TLR4/MD2 surface complex, triggers NLRP3/ASC-dependent inflammasome activation and cleavage of caspase-1, which processes pro-IL-1β into mature IL-1β [38, 39]. Surface TLR4/MD2 engagement also primes NF-κB signaling [42]. Intracellular LPS can be recognized by procaspase-11 (mouse) or procaspase-4 to -5 (in humans) and mount the noncanonical NLRP3/ASC inflammasome response to produce and secrete more IL-1β [38]. The type IV pilus-derived pilin, which directly activates caspase-1 without priming either NLRC4, NLRP3, or ASC, causes pro-IL-1β cleavage and its secretion [43]. As noted above, the switch to a biofilm mode of growth through the induction of c-di-GMP signaling limits the expression of PAMPs such as flagellin or PcrV, both NLRC4/NAIP inflammasome activators. This diminished expression of PAMPs is usually interpreted as bacterial strategy to avoid the activation of the inflammasome and resulting production of IL-1β and recruitment of phagocytes [28, 44]. However, several studies fail to demonstrate that inflammasome activation promotes *P. aeruginosa* clearance [39, 40, 45]. Mice lacking inflammasome components, or those that had been treated with anakinra, which blocks IL-1 signaling, in fact had significantly increased ability to clear *P. aeruginosa* [39]. These studies do not support the hypothesis that decreased expression of PAMPs is a bacterial mechanism to increase survival within the lung by limiting inflammation. It is suggested that the intense proinflammatory response elicited by the NLRC4-NLRP3 inflammasomes actually interferes with bacterial clearance, such as by activating autophagy-mediated *P. aeruginosa* protection inside macrophages [46], although other effects of inflammasome activation on the local milieu may also be involved. In addition, these studies do not take into consideration whether the same properties play a role in the clearance or conservation of long-term strains that cause chronic infections, which due to their adaptation and reduction of immunogenicity must use other mechanisms to enhance their survival.

**Host Immunity and Catabolite Repression-Mediated Biofilm Production**

Catabolite repression is a signaling pathway present in several pathogens, which in *P. aeruginosa* is mediated by the *crc* locus [47]. It is activated by succinate, a keto acid and intermediate of the TCA cycle, which produces ATP under O2 respiration and internal ROS. Succinate re-
stricts glucose and other nutrient utilization, such as amino acids and mannitol, committing *P. aeruginosa* metabolism to the TCA cycle to generate energy, as opposed to the bioenergetically more favorable Entner-Doudoroff and glyoxylate shunt pathways [48, 49]. Indeed, zwf, the gene that codes for the glucose 6-phosphate dehydrogenase enzyme (G6PDH) and that initiates the Entner-Doudoroff and pentose phosphate pathway, is negatively regulated by crc [47, 50]. Lack of zwf signaling promises the production of NADPH, the antioxidant molecule in charge of controlling excessive endogenous and exogenous ROS [26, 50]. Catabolite repression through Crc increases the accumulation of intracellular oxidative species, which, in addition to the ROS produced by the TCA cycle operation, boosts the probability of damaging DNA [22, 51]. As defenses against free radicals and ROS require upregulation of intracellular signaling such as zwf, selection of mutants that fulfill these requirements also promotes the generation of a biofilm lifestyle.

Acute pneumonia causes enormous airway damage, allowing cells leaking out their cytoplasmic contents. Many inflammatory reactions, such as the inflammatory cascade, activate pyroptosis and cell death with the release of intracellular contents [52]. These host-derived nutrients become available for *Pseudomonas* during acute pneumonia. Yet, the impact of these carbon sources on bacterial metabolism and pathogenicity remains to be established, influencing the predominance of glucose- or amino-acid-based metabolism of *P. aeruginosa*. Utilization of substrates for the TCA cycle and endogenous ROS production could promote the selection of mutants adapted to the newly available nutrients [22]. This ROS-mediated selection of oxidant-friendly clones and biofilm production is further supported by studies showing that either scavenging ROS with N-acetyl-L-cysteine [53] or deleting the crc locus [47], which primes c-di-GMP synthesis, modulates pilin formation and results in biofilm disruption [14]. Thus, organisms such as *P. aeruginosa* can readily alter their metabolism to a particular environment, even in the presence of recruited immune cells and phagocytes.

Augmented expression of Entner-Doudoroff (zwf) and glyoxylate shunt (aceA and glcB) regulatory genes in mucoid CF-related *P. aeruginosa* has been reported [54–56], which conferred advantages for sputum-mediated clearance. Of interest, zwf, aceA, and glcB were constitutively upregulated in mucoid CF isolates, suggesting that adaptation in late-stage CF may include the rewiring of the regulatory networks that control preferential use of metabolites. Whether defense against host immune clearance is increased by altered use of these metabolic pathways is not established; it is clear that the biofilm lifestyle acquired by chronic strains along their transformation into the mucoid phenotype is in response to the hostile surroundings produced by both the host and the bacterial metabolism itself.

Overall, despite decades of research using clinical isolates as well as many different in vivo and in vitro models, exactly how *P. aeruginosa* adapts to the milieu of the airways and overcomes innate immune clearance at other sites remains incompletely understood. Ongoing analyses of whole-genome sequencing data might provide a more encompassing view of the overall adaptive process, with the airway surface, the production of biofilms, and their interaction with the host immunity. The adaptive responses to common innate immune clearance mechanisms exploited by opportunistic bacteria are predicted to be similar. The opportunistic gram-negative bacterial genomes would be thought to have roughly the same repertoire of genes and metabolic capabilities. These organisms must all adapt to the same innate immune effectors, antimicrobial peptides, phagocytes, and oxidant stress. Nonetheless, it appears that there may be highly species-specific strategies employed by different pathogens, particularly in the setting of pneumonia.

**K. pneumoniae** Resistance to Innate Immune Clearance

*P. aeruginosa* and *K. pneumoniae* share a common ecological niche as major causes of health-care-associated infections, particularly pneumonia and sepsis [57]. As gram-negative pathogens with the ability to acquire exogenous DNA to confer antibiotic resistance, both can adapt to the milieu of human airways. *K. pneumoniae* in general produces extracellular polysaccharides that are associated with human colonization [58]. *K. pneumoniae* strains are relatively heterogeneous, with different phenotypes and genotypes associated with infection. Whereas the typical virulent serotypes, as typified by ATCC 43816 (KPPR1), have been widely studied, the carbapenem-resistant ST258 isolates, while less immunostimulatory in murine models, are increasingly prevalent and are associated with high rates of morbidity and mortality in humans [59]. Most notorious are the hypermucovirulent isolates often associated with liver abscess formation that are important causes of sepsis but in relatively limited geographic locales [60]. Carbapenem-resistant (CRKP) and even colistin-resistant strains have become more
endemic, colonizing healthy humans [61]. As an opportunistic, these MDR organisms can cause severe disease that is often difficult to treat, associated with persistent bacteremia and high mortality, and disproportionately affecting patients with comorbidities and critical illness (>50%) [62].

**K. pneumoniae Surface Structures Important in Pathogenesis: Production of Biofilm and Fimbriae**

Biofilm formation is a major characteristic of *K. pneumoniae* strains, seen especially in MDR and extensively drug-resistant isolates [63] (Fig. 2a). Mechanisms of biofilm formation such as c-di-GMP network regulation are common to gram-negative organisms, while capsular protein variability is unique to *K. pneumoniae*. Across characterized isolates, fimbriae and capsular protein are variably expressed reflecting their genetic diversity and differing contributions to pathogenicity [63, 64]. Like *P. aeruginosa*, *K. pneumoniae* utilizes c-di-GMP, a critical second messenger restricted to bacterial metabolism [65], to regulate type 1 and 3 fimbrial production and subsequent biofilm formation. Redundant and conserved components of the c-di-GMP network are found across clinical isolates of *K. pneumoniae* suggesting that c-di-GMP regulation plays a major role in virulence and/or colonization [66]. This has been corroborated in murine models of *K. pneumoniae* infection with levels of c-di-GMP influencing the extent of pathology. Elevated c-di-GMP levels...
Iron Scavenging and *K. pneumoniae*

A mechanism for iron acquisition is another shared property of *K. pneumoniae* and *P. aeruginosa*. For both pathogens, the presence of human lactoferrin in the airways interferes with biofilm formation [79, 80]. For *K. pneumoniae*, the production of several siderophores, including enteroactin (Ent+) and yersinobactin (Ybt+), provides a mechanism to compete for iron. Siderophores contribute significantly to the success of *K. pneumoniae* as a pathogen given the overrepresentation of organisms with increased expression of the major *K. pneumoniae* siderophores, the Ent+Ybt+ isolates, in the ST258 clade [81]. As a scavenger of iron, lactoferrin is a potential therapeutic that will inhibit the growth of *K. pneumoniae* [80]. However, the expression of capsular protein (cps) also plays a role in limiting interactions of the lactoferrin and the bacterial surface restricting its effect [82].

**Emergence of Hypervirulent *K. pneumoniae***

While the production of extracellular polysaccharides and proteins is a general feature of *K. pneumoniae* isolates, a subgroup of “hypervirulent” (hvKP) strains produce huge amounts of extracellular material [83]. This *Klebsiella* has been typically associated with bloodstream infections and liver abscesses leading to high mortality [84]. The epidemiology of the hypermucovirulent isolates and their related resistance mechanisms have been recently reviewed [85]. These organisms are usually of the capsular type K2, and whole-genome sequencing suggests several unique loci, distinct from those of other pathogenic *K. pneumoniae* strains [86]. In murine models, they cause lethality at 10^5 cfu inocula, which is in stark contrast to previously characterized CRKP isolates that require inocula 5–6 orders of magnitude to cause illness in murine models [87, 88]. *rpmA* mutations are thought to be responsible for the hypermucoviscous phenotype by increasing expression of capsular protein and thereby biofilm formation [89, 90].

Recent ST11 isolates of *K. pneumoniae* isolated from patients with ventilator-associated pneumonia have the hypervirulent phenotype and are also carbapenem resistant [91]. This alarming development is not unexpected given the proclivity of *Klebsiella* for acquiring extracellular DNA, and the hypervirulent phenotype is associated with the acquisition of a 170-kbp plasmid [91]. These strains have also been isolated from patients without predisposing conditions [61]. The acquisition of colistin resistance in these hypervirulent strains has also been reported, which appears to generate a fitness cost [60]. In vitro studies of both antibiotic-resistant and -susceptible *K. pneumoniae* strains indicate that, like *P. aeruginosa*, the organisms tend to revert to the biofilm mode of growth in stressful laboratory conditions [92], suggesting a common bacterial response to the oxidant stress of human airways and the resulting immune response.
Modification of surface PAMPs and capsular material is a well-recognized mechanism of immune evasion in Klebsiella. Sialic acid, a common feature of eukaryotic cell glycoproteins, is abundant in the expression of capsular protein of K. pneumoniae K1 isolates [95]. Sialic acid contributes to the hypermucoviscous phenotype and directly impedes interaction with and uptake by immune cells. Indirectly, binding of sialic acid to Siglec-9 on the surface of neutrophils interferes with neutrophil bactericidal activity [95]. On the other hand, other cell surface moieties, such as mannose residues, enhance the recognition of these organisms by immune cells [68, 96].

The modification of LPS is another widely conserved target for immune adaptation in many gram-negative organisms. This is an especially important site of mutation in the Klebsiella isolates with resistance to colistin, an antimicrobial that specifically targets the lipid A moiety of LPS. The colistin-resistant K. pneumoniae strains have altered LPS structures that limit the binding of the drug to the bacterial membrane [97]. Recent characterization of LPS from infected patients showed the rapid acquisition of genomic- and plasmid-mediated mutations, leading to alterations in the composition of lipid A and colistin resistance [98]. Perhaps the most concerning of these genetic elements is the emergence of the mobilized colistin resistance (mcr-1), a mobile plasmid rapidly shared amongst all members of the Enterobacteriaceae [99]. Whether or not these mutations carry a high fitness cost is not well established in humans. In a Galleria mellonella infection model, MCR-1-mediated resistance was associated with decreased fitness and attenuated cytokine production [100]. How the alterations in the structure of LPS affect immune cell recognition and subsequent immunogenicity has not been published to date.

**K. pneumoniae Resistance to Phagocytic Killing**

A major factor in the pathogenesis of *K. pneumoniae* infections that is replicated in murine models is the remarkable resistance of these organisms, particularly the carbapenem-resistant *K. pneumoniae* to phagocytic clearance. The exact mechanism by which these CRKP isolates avoid intracellular killing, particularly by neutrophils, has yet to be elucidated. In vitro studies have established that ST258 isolates, in contrast to the KPPR1 strain, are resistant to neutrophil killing ex vivo [101, 102]. Differences in the production of respiratory burst and ROS generation [103, 104] have been observed; however, no specific bacterial genes have been identified that correlate with this phenotype. The mechanisms appear to involve resistance to Ca²⁺-dependent killing [102]. It is clear that neutrophils and/or monocytes are critical to the host in clearance of ST258 isolates, as mice treated with anti-Ly6G antibodies have increased bacterial burden [102, 105]. One recent study utilized an anti-LPS-O-antigen antibody to increase opsonophagocytic killing capacity of neutrophils without loss of TLR4 signaling, likely from enhanced bacterial recognition by neutrophils [106]. However, this may not be universal as the ST258 isolates appear to be readily phagocytosed [87] but not killed [102], suggesting a mechanism by which intracellular killing processes are inhibited.

**Responses of Macrophages and Monocytes to *K. pneumoniae* Infection**

In addition to the limited killing capacity of neutrophils, in vivo the CRKP isolates have acquired additional mechanisms to thwart phagocytic clearance. Alveolar macrophages, the resident responders to pathogens in the airways, are critical to the clearance of *K. pneumoniae* pneumonia [107, 108]. The activation state and polarization of these macrophages are important in this process, as macrophages in the M2b or anti-inflammatory state were more susceptible to infection [109, 110]. Treating mice with GM-CSF to polarize macrophages to an inflammatory phenotype appeared to improve bacterial clearance [111]. However, a recent study with a CRKP isolate found that the removal of alveolar macrophages with clodronate liposomes does not change bacterial clearance [102]. Therefore, the role of resident alveolar macrophages in pulmonary infection with CRKP isolates of *K. pneumoniae* may be less essential.

Some studies with the classic *K. pneumoniae* KPPR1 have highlighted the key role of recruited monocytes in the pathogenesis of *K. pneumoniae* pneumonia [62, 112]. The function of monocytes in response to infection with the genetically and phenotypically diverse CRKP isolates is less clear. Monocyte-derived suppressor cell recruit-
ment has been identified as an important component in the resolution phase of *K. pneumoniae* KPPR1 infection [113]. These cells function in the clearance of infected and apoptotic neutrophils in an IL-10-dependent manner. However, the premature influx of these immunosuppressive monocytes (Ly6C+) in ST258 *K. pneumoniae* pneumonia interfered with neutrophil function and contributed to persistent infection [102]. Other groups have shown the central role of these Ly6C monocytes in the coordination and activation of Th17 cells in response to infection [114]. Subsequent bacterial clearance was dependent on the activation of these cells via the production of intracellular ROS. These discordant findings can most likely be explained by the observation that mononuclear cells infected with isolates from different clonal lineages of ST258 induced variable levels of Th17 expression in exposed T cells [115]. Again, these findings provide yet another example of the variability in the phenotype of these highly genetically variable organisms.

**Conclusions**

The success of certain gram-negative bacteria as human pathogens is due mainly to the genetic flexibility of these organisms, as they adapt to the milieu of the human airways and other sites of infection. Both *K. pneumoniae* and *P. aeruginosa* use c-di GMP signaling to assume the biofilm lifestyle which provides protection from phagocytes, antibiotic exposure, and oxidant stress. The biomass of the biofilm provides a sufficient population to support mutation in response to antibiotic and innate immune selective pressures. These pathogens, such as in the case of *K. pneumoniae*, also readily acquire exogenous DNA conferring many important phenotypes relevant to human disease, including both colistin resistance and the hypervirulent phenotype. The use of whole-genome sequencing highlights the substantial diversity of clinically prevalent isolates but may also lead to the identification of shared targets in both of these species, which could be exploited therapeutically.

The presence of different metabolites in the airways and their influence on the adaptive programs required to produce biofilm is less well understood. Whereas the consumption of glucose and synthesis of polysaccharides to construct the extracellular matrix is well accepted, utilization of keto acids or amino acids secreted by host cells is not established. As they may help “turning on” the switch of adaptation, they also arise as possible targets for therapy. There are scattered reports supporting this hypothesis; the use of specific carbon substrates to deregulate biofilm production is attractive as an alternative to antibiotics. Future research must also focus on comprehensive analyses of bacterial metabolomics to better understand the biochemistry behind host-pathogen adaptation and identify metabolic targets to disrupt bacterial colonization.

**Acknowledgments**

A.P. is supported by NIH 1R35HL135800. S.A.R. is supported by a CFF Postdoctoral Fellowship (CFF RIQUEL 17F0/PG00837). D.A. is supported by NIH 1K08HL138289.

**Disclosure Statement**

Authors declare no conflict of interest exist.

**References**

1. Elborn JS: Cystic fibrosis. Lancet 2016;388:2519–2531.
2. Gutierrez HH, Sanchez I, Schidlow DV: Cystic fibrosis care in Chile. Curr Opin Palm Med 2009;15:632–637.
3. Silva Filho LV, Castanos C, Ruiz HH: Cystic fibrosis in Latin America – improving the awareness. J Cyst Fibros 2016;15:791–793.
4. Masekela R, Zampoli M, Westwood AT, White DA, Green RJ, Olorunju S, Kwofe-Mensah M: Phenotypic expression of the 3120+1G>A mutation in non-Caucasian children with cystic fibrosis in South Africa. J Cyst Fibros 2013;12:363–366.
5. Westwood T, Henderson B, Ramsay M; Medical and Scientific Advisory Committee of the South African Cystic Fibrosis Association: Diagnosing cystic fibrosis in South Africa. S Afr Med J 2006;96:304, 306.
6. Wine JJ, Hansson GC, Konig P, Joo NS, Er mund A, Pieper M: Progress in understanding mucus abnormalities in cystic fibrosis air ways. J Cyst Fibros 2018;17:S35–S39.
7. Babaras AS, Dib MJ, Al-Adra DP, Golderacena N, Sapisochin G, Waddell TK, Keshayvje S, Selznar N, Chaparro C, Catrall MS: Combined lung-liver-pancreas transplantation in a recipient with cystic fibrosis. J Cyst Fibros 2018;17:e1–e4.
8. Lowery EM, Adams W, Grim SA, Clark NM, Edwards L, Layden JE: Increased risk of PTLD in lung transplant recipients with cystic fibrosis. J Cyst Fibros 2017;16:727–734.
9. Cohen TS, Prince A: Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012; 18:509–519.
10. Riquelme SA, Hopkins BD, Wolfe AL, Di-Mango E, Kitur K, Parsons R, Prince A: Cystic fibrosis transmembrane conductance regulator attaches tumor suppressor PTEN to the membrane and promotes anti Pseudomonas aeruginosa immunity. Immunity 2017;47: 1169–1181.e7.
14 Valentini M, Guevene ZT, Harwood CS: Subcellular clustering of the phosphorylated WspR response regulator protein stimulates its diguanylate cyclase activity. MBio 2013;4:e00242-13.

15 Valenti M, Filloux A: Biofilms and cyclic di-GMP (c-di-GMP) signaling: lessons from Pseudomonas aeruginosa and other bacteria. J Biol Chem 2016;291:12547–12555.

16 Colvin KM, Irie Y, Tart CS, Urbano R, Whitney JC, Ryder C, Marmont LS, Sadovskaya I, Secor PR, Wozniak DJ: Pseudomonas aeruginosa AlgN. J Bacteriol 1997;179:3711–3720.

17 Meyer S, Hohberger CD, Shankar S, Ye RW, Chakrabarty AM: Sigma factor-anti-sigma factor interaction in alginate synthesis: inhibition of AlgT by MucA. J Bacteriol 1996;178:4990–4996.

18 Irie Y, Roberts AEL, Kragh KN, Gordon VD, Hutchison J, Allen RJ, Melaugh G, Bjarnsholt T, West SA, Diggle SP: The Pseudomonas aeruginosa Psl polysaccharide is a social but noncheat trait in biofilms. MBio 2017;8:e00374-17.

19 Xu Z, Zha NJ, Bierberi M, Ye RW, Chakrabarty AM: Sigma factor-anti-sigma factor interaction in alginic acid synthesis: inhibition of AlgT by MucA. J Bacteriol 1996;178:4990–4996.

20 Matthew K, McPherson CJ, Ohman DE: Post-translational control of the algT (algU) encoded sigma22 for expression of the alginate regulons in Pseudomonas aeruginosa and localization of its antagonist proteins MucA and MucB (AlgN). J Bacteriol 1997;179:3711–3720.

21 Deretic V, Schurr MJ, Yu H: Pseudomonas aeruginosa, mucoidity and the chronic infection phenotype in cystic fibrosis. Trends Microbiol 1995;3:351–356.

22 Boles BR, Singh PK: Endogenous oxidative stress promotes diversity and adaptability in biofilm communities. Proc Natl Acad Sci USA 2008;105:12503–12508.

23 Meylan S, Porter CBM, Yang JH, Belenyk P, Gutierrez A, Lobritz MA, Park J, Kim SH, Moskovitz SM, Collins JJ: Carbon sources tune antibiotic susceptibility in Pseudomonas aeruginosa via tricarboxylic acid cycle control. Cell Chem Biol 2017;24:195–206.

24 Behrends V, Bell TJ, Liebeke M, Cords-Blaubert A, Ashraf SN, Nair C, Zlosnik JE, Williams HD, Bundy JG: Metabolic profiling to characterize disease-related bacteria: glucolactone excretion by Pseudomonas aeruginosa mutants and clinical isolates from cystic fibrosis patients. J Biol Chem 2013;288:15098–15109.

25 Behrends V, Ryall B, Zlosnik JE, Speert DP, Bundy JG, Williams HD: Metabolic adaptations of Pseudomonas aeruginosa during cystic fibrosis chronic lung infections. Environ Microbiol 2013;15:398–408.

26 Ma JF, Hager PW, Howell ML, Phibbs PV, Hassett DJ: Cloning and characterization of the Pseudomonas aeruginosa zwf gene encoding glucose-6-phosphate dehydrogenase, an enzyme important in resistance to barrier surface/viologen (paraquat). J Bacteriol 1998;180:1741–1749.

27 Ahn S, Jung J, Jang IA, Madsen EL, Park W: Role of glyoxylate shunt in oxidative stress response. J Biol Chem 2016;291:11928–11938.

28 Jain M, Ramirez D, Seshadri R, Cullina JP, Powers CA, Schulte GS, Bar-Beir M, Sulli van CL, McColley SA, Hauser AR: Type III secretion phenotypes of Pseudomonas aerugi nosa strains change during infection of individuals with cystic fibrosis. J Clin Microbiol 2004;42:5229–5237.

29 Pankhaniya RR, Tamura M, Allmond LR, Moriyama K, Ajayi T, Wiener-Kronish JP, Sawa T: Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU. Crit Care Med 2004;32:2293–2299.

30 Salacha R, Kovacic F, Brochier-Armanet C, Marmont LS, Sadovskaya I, Secor PR, Wozniak DJ: Psl produced by mucoid strains of Pseudomonas aeruginosa is a social but noncheat trait in biofilms. MBio 2017;8:e00242-13.

31 Drenkard E, Ausubel FM: Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002;416:740–743.

32 Jones CJ, Wozniak DJ: Psl produced by mucoid Pseudomonas aeruginosa contributes to the establishment of biofilms and immune evasion. MBio 2017;8:e00864-17.

33 Sonnenberg GF, Fouser LA, Artis D: Borderosomes: mechanism of action, role in disease, and therapeutic potential. Nat Rev Microbiol 2010;8:1498–1512.

34 Drenkard E, Ausubel FM: Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002;416:740–743.

35 Kim SH, Moskovitz SM, Collins JJ: Carbon sources tune antibiotic susceptibility in Pseudomonas aeruginosa via tricarboxylic acid cycle control. Cell Chem Biol 2017;24:195–206.

36 LI SA, Liu J, Xiang Y, Wang YJ, Lee WH, Zhang Y: Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis. Antimicrob Agents Chemother 2014;58:3144–3150.

37 Huber P, Basso P, Reboud E, Attree I: Pseudomonas aeruginosa renews its virulence factors. Environ Microbiol Rep 2016, Epub ahead of print.

38 Guo H, Callaway JB, Ting JP: Inflammomasomes: mechanism of action, role in disease, and therapeutic potential. Nat Med 2015;21:667–678.

39 Iannitti RG, Napolioli V, Oikonomou V, De Luca A, Galosi C, Pariano M, Massi-Benedetti C, Borghi M, Puccetti M, Lucidi V, Colombo B, Fiscarelli E, Lass-Florl C, Majo F, Cariani L, Russo M, Porcaro L, Ricciotti G, Elle-munter H, Ratcliff L, De Benedicts FM, Talesa VN, Dinarolo CA, van de Veerdonk FL, Romani L: IL-1 receptor antagonist ameliorates inflammation downstream of an NLRP3 inflammasome in murine and human cystic fibrosis. Nat Commun 2016;7:10791.

40 Cohen TS, Prince AS: Activation of inflammasome signaling mediates pathologic response in acute P. aeruginosa pneumonia. J Clin Invest 2013;123:1630–1637.

41 Pena J, Fu Z, Schwarzer C, Machen TE: Pseudomonas aeruginosa inhibition of flagellin-activated NF-κB and interleukin-8 by human airway epithelial cells. Infect Immun 2009;77:2857–2865.

42 Andreakos E, Sarec SM, Smith C, Lundberg A, Kariakidis S, Stonehouse T, Monaco C, Feldmann M, Foxwell BM: Distinct pathways of LPS-induced NF-κB activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood 2004;103:2229–2237.

43 Arlehamn CS, Evans TJ: Pseudomonas aeruginosa pilin activates the inflammasome. Cell Microbiol 2011;13:388–401.

44 Huus KE, Joseph J, Zhang L, Wong A, Aaron SD, Mah TF, Sad S: Clinical isolates of Pseudomonas aeruginosa from chronically infected cystic fibrosis patients fail to activate the inflammasome during both stable infection and pulmonary exacerbation. J Immunol 2016;196:3097–3108.

45 Schultz MJ, Rijnvedel AW, Florquin S, Edwards CK, Dinarolo CA, van der Poll T: Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 2002;282:L285–L290.

46 Deng Q, Wang Y, Zhang Y, Li M, Li D, Huang X, Wu Y, Pu J, Wu M: Pseudomonas aeruginosa triggers macrophage autophagy to escape intracellular killing by activation of the NLRP3 inflammasome. Infect Immun 2015;83:56–66.

47 O’Toole GA, Gibbs KA, Hager PW, Phibbs PV Jr, Kolter R: The global carbon metabolism regulator Ccr1 is a component of a signal transduction pathway required for biofilm development by Pseudomonas aeruginosa. J Bacteriol 2000;182:425–432.
Bacterial Adaptation to the Airways

Collier DN, Hager PW, Phibbs PV Jr: Catabolite repression control in the Pseudomonads. Res Microbiol 1996;147:551–561.

Rojo F: Carbon catabolite repression in Pseudomonas: optimizing metabolic versatility and interactions with the environment. FEMS Microbiol Rev 2010;34:658–684.

Kim J, Jeon CO, Park W: Dual regulation of zwf-1 by both 2-keto-3-deoxy-6-phosphogluconate and oxidative stress in Pseudomonas putida. Microbiology 2008;154:3905–3916.

Linares JF, Moreno R, Fajardo A, Martinez-Solano L, Escalante R, Rojo F, Martinez JL: The global regulator Crc modulates metabolism, susceptibility to antibiotics and virulence in Pseudomonas aeruginosa. Environ Microbiol 2010;12:3196–3212.

Martín-Sanchez F, Diamond C, Zeitler M, Solano L, Escalante R, Rojo F, Martinez JL: Adaptations of Pseudomonas aeruginosa to the cystic fibrosis lung environment can include deregulation of zwf, encoding glucose-6-phosphate dehydrogenase. J Bacteriol 2005;187:7561–7568.

Hagins JM, Scofield J, Suh SJ, Silo-Suh L: Influence of RpoN on isocitrate lyase activity in Pseudomonas aeruginosa. Microbiology 2010;156:1210–1211.

Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Ma–Zang ZG, Peng HL: Fur-dependent MrkHI regulation of type 3 fimbriae in Klebsiella pneumoniae. J Bacteriol 2011;193:3433–3460.

Shon AS, Bajwa RP, Russo TA: Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breeder. Virulence 2013;4:107–118.

Satlin MJ, Chen L, Patel G, Gomez-Simmonds A, Westwood A, Kim AC, Seo SK, Rosen- thal ME, Sperber SJ, Jenkins SG, Hamula CL, Uhlemann AC, Levi MH, Fries BC, Tang YW, Juretschko S, Rojtanad MJ, Hong T, Mathema B, Jacobs MR, Walsh TJ, Bonomo RA, Kreiswirth BN: Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States. Antimicrob Agents Chemother 2017;61:e02349-16.

Duvoigt C, Longo F, Pacisolin C, Donelli G, Balice MP, Libori MF, Tirachica V, Salvia A, Valarao PF: Biofilm formation and antibiotic resistance in Klebsiella pneumoniae urinary strains. J Appl Microbiol 2013;115:1003–1018.

Lawlor MS, Hsu J, Rick PD, Miller VL: Identification of Klebsiella pneumoniae virulence determinants using an intranasal infection model. Mol Microbiol 2005;58:1054–1073.

Tamao R, Pratt JT, Camalli A: Roles of cyclic di-guanulate in the regulation of bacterial pathogenesis. Annu Rev Microbiol 2007;61:131–148.

Crus DP, Huertas MG, Lozano M, Zambra MM: Comparative analysis of diguanylate cyclase and phosphodiesterase genes in Klebsiella pneumoniae. BMC Microbiol 2012;12:139.

Rosen DA, Twentyman J, Hunstad DA: High levels of cyclic di-GMP in Klebsiella pneumoniae attenuate virulence in the lung. Infect Immun 2018;86:e00647-17.

Sahly H, Navon-Venezia S, Roessler L, Hay A, Carmeli Y, Podsuhn R, Hennequin C, Forestier C, Ofek I: Extended-spectrum β-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in Klebsiella pneumoniae. Antimicrob Agents Chemother 2008;52:3029–3034.

Sebhaghi TA, Korhonen TK, Hornick DB, Clegg S: Characterization of the type 3 fimbrial adhesins of Klebsiella strains. Infect Immun 1998;66:2887–2894.

Sebhaghi TA, Clegg S: Construction and characterization of mutations within the Klebsiella mrkD1P gene that affect binding to collagen type V. Infect Immun 1999;67:1672–1676.

Wilksch J, Yang J, Clements A, Gabele JB, Short KR, Cao H, Cavaliere R, James CE, Whitchurch CB, Schermb MA, Chuaul ML, Liang ZX, Wijburg OL, Jenney AW, Lithgow TJ, Strugnell RA: MrkH, a novel c-di-GMP-dependent transcriptional activator, controls Klebsiella pneumoniae biofilm formation by regulating type 3 fimbriae expression. PLoS Pathog 2011;7:e100204.

Tan JW, Wilksch JJ, Hocking DM, Wang N, Srikhanta YN, Tauschek M, Lithgow T, Roberts-Browne RM, Yang J, Strugnell RA: Positive autoregulation of mrkH by the cyclic di-GMP-dependent MrkH protein in the biofilm regulatory circuit of Klebsiella pneumoniae. J Bacteriol 2015;197:1659–1667.

Wu CC, Lin CT, Cheng WY, Huang CJ, Wang ZC, Peng HL: Fur-dependent MrkH regulation of type 3 fimbriae in Klebsiella pneumoniae CG43. Microbiology 2012;158:1045–1056.

Johnson JG, Murphy CN, Sippy J, Johnson TJ, Clegg S: Type 3 fimbriae and biofilm formation are regulated by the transcriptional regulators MrkHI in Klebsiella pneumoniae. J Bacteriol 2011;193:3433–3460.

Li Y, Li ZJ, Han WY, Ma LE, Sun CJ, Feng X, Du DT, Du TF, Gu JM: Identification and characterization of Th cell epitopes in MrkD adhesin of Klebsiella pneumoniae. Microb Pathog 2010;49:8–13.

Lavender H, Jagnow JJ, Clegg S: Klebsiella pneumoniae type 3 fimbria-mediated immunity to infection in the murine model of respiratory disease. Int J Med Microbiol 2005;295:293–299.

Johnson JG, Clegg S: Role of MrkJ, a phosphodiesterase, in type 3 fimbrial expression and biofilm formation in Klebsiella pneumoniae. J Bacteriol 2010;192:3944–3950.

Karaolis DK, Newstead MW, Zeng X, Hyodo M, Hayakawa Y, Bhan U, Liang H, Standiford TJ: Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia. Infect Immun 2007;75:4942–4950.

Singh PK, Parsek MR, Greenberg EP, Welsh MJ: A component of innate immunity prevents bacterial biofilm development. Nature 2002;417:552–555.

Moric P, Florio W, Rizzato C, Ghelardi E, Tagliavini A, Rossolini GM, Lupetti A: Synergistic activity of synthetic N-terminal peptide of human lactoferrin in combination with various antibiotics against carbapenem-resistant Klebsiella pneumoniae strains. Eur J Clin Microbiol Infect Dis 2017;36:1739–1748.

Bachman MA, Oyler JE, Burns SH, Caza M, Lepine F, Dozois CM, Weiser JN: Klebsiella pneumoniae versiniabactin promotes respiratory tract infection through evasion of lipo- calin 2. Infect Immun 2011;79:3309–3316.

Clegg S, Morgan CA, Yargas AP, Pagueiro V, Llop- mart CM, Alberti S, Bongechea JA: Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun 2004;72:7107–7114.

Paczosa MK, Mecas J: Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev 2016;80:153–169.

Ko WC, Paterson DL, Saginmeni AJ, Hansen DS, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazinoglu L, Trenholme G, Klugman KP, McCormack JG, Yu VL: Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis 2002;8:160–166.

Lee CR, Lee JH, Park KS, Jeon JH, Kim YB, Cha CJ, Jeong BC, Lee SH: Antimicrobial resistance of hypervirulent Klebsiella pneumoniae: epidemiology, hypervirulence-associated determinants, and resistance mechanisms. Front Cell Infect Microbiol 2017;7:483.
90 Cheng HY, Chen YS, Wu CY, Chang HY, Lai YC, Peng HL: RmpA regulation of capsular polysaccharide biosynthesis in Klebsiella pneumoniae CG43. J Bacteriol 2010; 192: 3144–3158.

91 Du P, Zhang Y, Chen C: Emergence of carbapenem-resistant hypervirulent Klebsiella pneumoniae. Lancet Infect Dis 2018; 18:23–24.

92 Anes J, Hurley D, Martins M, Fanning S: Exploring the genome and phenotype of multidrug resistant Klebsiella pneumoniae of clinical origin. Front Microbiol 2017;8:1913.

93 Gomez-Simmonds A, Uhlemann AC: Clinical implications of genomic adaptation and evolution of carbapenem-resistant Klebsiella pneumoniae. J Infect Dis 2017;215:S18–S27.

94 Parker D, Ahn D, Cohen T, Prince A: Innate immune signaling activated by MDR bacteria in the airway. Physiol Rev 2016;96:19–53.

95 Lee CH, Chang CC, Liu JW, Chen RF, Yang KD: Sialic acid involved in hypermucoviscosity phenotype of Klebsiella pneumoniae and associated with resistance to neutrophil phagocytosis. Virulence 2014;5:673–679.

96 Kabha K, Nissimov L, Athamana A, Keisari Y, Parolis H, Parolis LA, Grue RM, Schlepper-Schaffer J, Ekezwokot AR, Ohman DE, et al: Relationships among capsular structure, phagocytosis, and mouse virulence in Klebsiella pneumoniae. Infect Immun 1995;63:847–852.

97 Olaitan AO, Morand S, Rolain JM: Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol 2014;5:643.